Pharmaceutical giant AstraZeneca intends to dedicate a staggering $50 billion for the expansion of U.S. manufacturing and research & development (R&D) operations.
AstraZeneca, a leading pharmaceutical company, has announced an ambitious $50 billion investment plan in the United States by 2030, aiming to expand its medicines manufacturing and research & development (R&D) capabilities[1][2][3]. This significant investment is expected to create tens of thousands of high-skilled jobs across the country, strengthening the U.S. domestic supply chain for medicines.
Key details and locations include:
- **Virginia**: AstraZeneca will build a multi-billion-dollar drug substance manufacturing facility, marking the largest and most expensive plant in the company's history. The exact site within Virginia is yet to be determined. The company plans to invest $4 billion in Virginia alone, and the deal was completed rapidly, within 33 days, reflecting a strong partnership with the state[2].
- **Maryland**: AstraZeneca opened a $300 million cell therapy manufacturing plant in Maryland in May 2025. This site uses CAR-T cell therapy to treat blood cancers like lymphoma and leukemia[1].
- The investment is a continuation of a previous $3.5 billion capital investment announced in late 2024, focused on R&D and manufacturing in the U.S.[1][2].
This investment supports AstraZeneca's goal to grow U.S. sales from 42% to 50% of its total revenue by 2030, aiming for $80 billion in sales globally by the end of the decade[1][2]. The investment also aligns with the U.S. government's push to strengthen domestic pharmaceutical production amid tariff considerations on imported medicines[2].
The new facility in Virginia will focus on producing active pharmaceutical ingredients for AstraZeneca's weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9, and various combination small-molecule products[4]. Additionally, the investment will feature manufacturing facilities for cell therapy in Rockville, Maryland, and Tarzana, California.
The investment will span across AstraZeneca's extensive U.S. R&D and manufacturing footprint, including Gaithersburg, Maryland, Kendall Square, Cambridge, Massachusetts, Rockville, Maryland, Tarzana, California, Mount Vernon, Indiana, Coppell, Texas, and new sites focused on supplying clinical trials[4].
The investment in Virginia will create hundreds of highly skilled jobs, and the facilities will utilize AI, automation, and data analytics. This investment further advances technological advancements in pharmaceutical manufacturing and underscores AstraZeneca's commitment to innovation.
Howard Lutnick, US Secretary of Commerce, praised AstraZeneca's decision to bring substantial pharmaceutical production to the US, stating that "this investment will have a significant impact on our economy and our people, creating jobs and driving innovation in the pharmaceutical sector."[2]
Pascal Soriot, CEO of AstraZeneca, expressed belief in America's innovation in biopharmaceuticals and commitment to patients, stating that "we are committed to investing in America, where we see tremendous potential for innovation and growth in biopharmaceuticals, and where our patients rely on us to deliver life-changing medicines."[2]
In summary:
| Location | Investment Details | Purpose | |-------------|----------------------------------------------------|----------------------------------| | Virginia | $4 billion plant (largest in company history) | Drug substance manufacturing | | Maryland | $300 million cell therapy manufacturing facility | CAR-T cell therapy for blood cancers | | United States (general) | $50 billion total by 2030 (including $3.5 billion earlier) | Expanding R&D, manufacturing, supply chain, high-skilled jobs |
This investment marks AstraZeneca’s largest single manufacturing and R&D commitment in the U.S. to date[1][2][3]. The investment also builds upon a previous $3.5 billion U.S. investment announced in November 2024. This investment aims to reinforce America's global leadership in pharmaceutical manufacturing and R&D. Governor Glenn Youngkin of the Commonwealth of Virginia expressed support for the investment, further emphasizing the partnership between AstraZeneca and the state.
- AstraZeneca's $4 billion investment in Virginia will fund the construction of a multi-billion-dollar drug substance manufacturing facility, a significant move in their financing strategy for business expansion.
- The ongoing $50 billion investment plan by AstraZeneca includes finance for research and development facilities, such as the $300 million cell therapy manufacturing plant in Maryland, aimed at bolstering the pharmaceutical industry through innovation and high-skilled job creation.
%20operations.){kind=link}